Nuvation Bio Inc
NUVB2.275USD
+0.045+2.02%
Market hours （ET）Quotes delayed by 15 min
773.14MMarket Cap
LossP/E TTM
More Details of Nuvation Bio Inc Company
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Company Info
Ticker SymbolNUVB
Company nameNuvation Bio Inc
IPO dateJul 01, 2020
CEODr. David T. Hung, M.D.
Number of employees220
Security typeOrdinary Share
Fiscal year-endJul 01
Address357 Tehama Street, Floor 3
CitySAN FRANCISCO
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code94103
Phone14157543517
Websitehttps://www.nuvationbio.com/
Ticker SymbolNUVB
IPO dateJul 01, 2020
CEODr. David T. Hung, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Ms. Stacy Markel
Ms. Stacy Markel
Chief People Officer
Chief People Officer
10.00K
--
Mr. Philippe Sauvage
Mr. Philippe Sauvage
Chief Financial Officer and Principal Financial Officer
Chief Financial Officer and Principal Financial Officer
7.30K
--
Mr. Robert B. (Rob) Bazemore, Jr.
Mr. Robert B. (Rob) Bazemore, Jr.
Lead Independent Director
Lead Independent Director
5.00K
--
Mr. Joe Rayne
Mr. Joe Rayne
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. David T. Hung, M.D.
Dr. David T. Hung, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
60.28M
+0.84%
Mr. Kim D. Blickenstaff
Mr. Kim D. Blickenstaff
Independent Director
Independent Director
172.19K
--
Dr. Robert Mashal, M.D.
Dr. Robert Mashal, M.D.
Independent Director
Independent Director
100.00K
--
Ms. Colleen Sjogren
Ms. Colleen Sjogren
Chief Commercial Officer
Chief Commercial Officer
78.00K
+178.57%
Ms. Kerry A. Wentworth
Ms. Kerry A. Wentworth
Chief Regulatory Officer
Chief Regulatory Officer
50.00K
--
Mr. Moses Makunje, CPA
Mr. Moses Makunje, CPA
Principal Accounting Officer, Vice President - Finance
Principal Accounting Officer, Vice President - Finance
10.61K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
Shareholders
Shareholders
Proportion
Hung (David T)
17.72%
Fidelity Management & Research Company LLC
14.70%
Decheng Capital LLC
7.63%
BlackRock Institutional Trust Company, N.A.
4.66%
The Vanguard Group, Inc.
4.51%
Other
50.78%
Shareholder Types
Shareholders
Proportion
Investment Advisor
30.97%
Individual Investor
19.30%
Hedge Fund
12.40%
Investment Advisor/Hedge Fund
9.48%
Venture Capital
8.02%
Research Firm
1.03%
Bank and Trust
0.20%
Pension Fund
0.17%
Private Equity
0.01%
Other
18.42%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
340
277.65M
81.60%
-29.03M
2025Q1
346
276.31M
81.30%
-31.14M
2024Q4
336
290.52M
86.58%
+4.56M
2024Q3
324
278.55M
83.07%
+36.83M
2024Q2
323
221.78M
89.68%
-2.09M
2024Q1
305
194.38M
89.06%
-41.04M
2023Q4
290
194.02M
89.00%
-35.90M
2023Q3
285
196.95M
90.37%
-25.21M
2023Q2
286
199.03M
91.34%
-20.86M
2023Q1
290
197.27M
90.57%
-23.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hung (David T)
60.28M
17.72%
+500.00K
+0.84%
Jun 16, 2025
Fidelity Management & Research Company LLC
50.03M
14.7%
+5.31M
+11.88%
Mar 31, 2025
Decheng Capital LLC
25.95M
7.63%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
15.87M
4.66%
-60.61K
-0.38%
Mar 31, 2025
The Vanguard Group, Inc.
15.34M
4.51%
-334.75K
-2.14%
Mar 31, 2025
Omega Fund Management, LLC
13.07M
3.84%
--
--
Mar 31, 2025
Laurion Capital Management LP
9.87M
2.9%
+3.38M
+52.06%
Mar 31, 2025
Octagon Capital Advisors LP
7.90M
2.32%
-1.30M
-14.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.13M
1.51%
+179.41K
+3.62%
Mar 31, 2025
State Street Global Advisors (US)
4.86M
1.43%
+256.02K
+5.57%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
SPDR S&P Pharmaceuticals ETF
0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.63%
ALPS Medical Breakthroughs ETF
0.45%
iShares U.S. Pharmaceuticals ETF
0.25%
iShares Micro-Cap ETF
0.11%
iShares Health Innovation Active ETF
0.08%
Avantis US Small Cap Equity ETF
0.06%
iShares Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.97%
SPDR S&P Pharmaceuticals ETF
Proportion0.89%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.63%
ALPS Medical Breakthroughs ETF
Proportion0.45%
iShares U.S. Pharmaceuticals ETF
Proportion0.25%
iShares Micro-Cap ETF
Proportion0.11%
iShares Health Innovation Active ETF
Proportion0.08%
Avantis US Small Cap Equity ETF
Proportion0.06%
iShares Biotechnology ETF
Proportion0.05%
Fidelity Enhanced Small Cap ETF
Proportion0.04%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
